Dobutamine as selective 1-adrenoceptor agonist in in vivo studies
on human thermogenesis and lipid utilization.
Schiffelers, S. L. H., V. J. A. Van Harmelen, H. A. J. De Grauw, W. H.
M. Saris, and M. A. Van Baak.
Nutrition Toxicology and Environment Research Institute Maastricht,
Department of Human Biology, Maastricht University, Maastricht, The
Netherlands
APStracts 6:0248A, 1999.
The use of dobutamine as selective 1-adrenoceptor agonist in in vivo
studies on human thermogenesis and lipid utilization was investigated
in twenty males. At 2.5, 5 and 10 g/kgmin, dobutamine induced
significant increases in energy expenditure, lipid oxidation and
lipolysis. The 1-adrenoceptor antagonist atenolol (bolus: 42.5 g/kg,
infusion: 1.02 g/kgmin) blocked all dobutamine-induced effects on
thermogenesis and lipid utilization. All parameters remained at
levels comparable with those during saline infusion. The used dose of
atenolol did not inhibit 2-adrenoceptor-specific changes in energy
expenditure, lipid oxidation and lipolysis during salbutamol infusion
(85 ng/kgmin). This indicates that atenolol was specific for 1
-adrenoceptors and did not camouflage concomitant 2-adrenoceptor
stimulation during dobutamine infusion. Therefore we conclude that
dobutamine can be used as a selective 1-adrenoceptor agonist at
dosages 10 g/kgmin in in vivo studies on human thermogenesis and
lipid utilization.
Received 16 September 1998; accepted in final form 26 May 1999.
APS Manuscript Number A822-8.
Article publication pending Journal of Applied Physiology.
ISSN 1080-4757 Copyright 1999 The American Physiological Society.
Published in APStracts on 14 June 1999